phosphorus has been researched along with maxacalcitol in 17 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (maxacalcitol) | Trials (maxacalcitol) | Recent Studies (post-2010) (maxacalcitol) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 270 | 35 | 58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, A; Dusso, AS; Finch, J; Kamimura, S; Lopez-Hilker, S; Mori, T; Negrea, L; Nishii, Y; Slatopolsky, E | 1 |
| Akeno, N; Horiuchi, N; Kimura, S; Saikatsu, S | 1 |
| Friedler, RM; Geng, Z; Kubodera, N; Malluche, HH; Monier-Faugere, MC; Qi, Q; Slatopolsky, E | 1 |
| Ihara, K; Ikeda, K; Kawai, S; Merida, L; Shigetomi, M; Sugiyama, T; Tsubone, T; Yamaguchi, A | 1 |
| Hasegawa, T; Ideura, T; Koiwa, F; Kojima, I | 1 |
| Fujimura, A; Tsuruoka, S; Wakaumi, M; Yamamoto, H | 1 |
| Hayashi, M; Ichihara, A; Itaya, Y; Kobayashi, K; Monkawa, T; Nakamura, R; Takenaka, T; Tsuchiya, Y; Yoshizawa, M | 1 |
| Akagi, S; Ichikawa, H; Kihara, T; Kohmoto, H; Kumagai, I; Makino, H; Morimoto, H; Nakao, K; Wada, J; Yano, A | 1 |
| Ikeda, Y; Takemoto, F | 1 |
| Hayakawa, H; Hirano, K; Kawamura, Y; Shigematu, T; Yamamoto, I | 1 |
| Ando, R; Chida, Y; Hata, T; Inagaki, Y; Inoue, A; Ishida, Y; Naito, S; Ohtsuka, M; Tachibana, K; Takayama, M | 1 |
| Fukagawa, M; Itoh, K; Matsushita, K; Tanaka, M | 1 |
| Chiba, E; Sugawara, G | 1 |
| Kumafuji, M; Momose, M; Sodeyama, T; Suzawa, T; Tokoo, M; Yamada, Y | 1 |
| Imanishi, Y; Inaba, M; Kawakami, A; Matsumoto, S; Miki, T; Mitani, S; Naka, H; Nishizawa, Y; Nozaki, K; Shimizu, G | 1 |
| Asaka, M; Matsumoto, Y; Oyama, Y; Saito, A; Yokoyama, H | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Kurita, N; Kurokawa, K; Onishi, Y; Yokoyama, K | 1 |
2 review(s) available for phosphorus and maxacalcitol
| Article | Year |
|---|---|
[Serum calcium concentration and the safety of vitamin D therapy].
Topics: Administration, Oral; Calcitriol; Calcium; Drug Administration Schedule; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Infusions, Intravenous; Kidney Failure, Chronic; Monitoring, Physiologic; Parathyroid Hormone; Phosphorus; Pulse Therapy, Drug; Vitamin D; Vitamin D Deficiency | 2004 |
[Therapy for ROD and measurement of the bone mass].
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Vitamin K 2 | 2004 |
2 trial(s) available for phosphorus and maxacalcitol
| Article | Year |
|---|---|
Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
Topics: Administration, Oral; Adult; Aged; Calcitriol; Calcium; Ethanol; Female; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Osmolar Concentration; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome | 2003 |
Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Topics: Alkaline Phosphatase; Bone and Bones; Calcitriol; Calcium; Calcium Channel Agonists; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis | 2004 |
13 other study(ies) available for phosphorus and maxacalcitol
| Article | Year |
|---|---|
The effect of 22-oxacalcitriol on serum calcitriol.
Topics: Animals; Antineoplastic Agents; Calcitriol; Calcium; Dose-Response Relationship, Drug; Female; Metabolic Clearance Rate; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Rats; Rats, Inbred Strains | 1992 |
Induction of vitamin D 24-hydroxylase messenger RNA and activity by 22-oxacalcitriol in mouse kidney and duodenum. Possible role in decrease of plasma 1 alpha,25-dihydroxyvitamin D3.
Topics: Animals; Calcitriol; Calcium; Cytochrome P-450 Enzyme System; Duodenum; Enzyme Induction; Kidney; Male; Mice; Phosphorus; RNA, Messenger; Steroid Hydroxylases; Vitamin D3 24-Hydroxylase | 1994 |
22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Topics: Animals; Bone Diseases, Metabolic; Bone Remodeling; Calcitriol; Calcium; Disease Models, Animal; Dogs; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Nephrectomy; Parathyroid Hormone; Phosphorus; Time Factors | 1999 |
Effects of vitamin D analog, 22-oxa-1,25-dihydroxyvitamin D(3), on bone reconstruction by vascularized bone allograft.
Topics: Amino Acids; Animals; Antineoplastic Agents; Bone Transplantation; Bone Wires; Calcitriol; Calcium; Cyclosporine; Fibula; Graft Survival; Immunosuppressive Agents; Male; Phosphorus; Rats; Rats, Inbred Lew; Tibia; Transplantation, Homologous | 2002 |
Chronopharmacology of oxacalcitriol in rat model of osteoporosis.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Body Weight; Bone Density; Calcitriol; Calcium; Creatinine; Dose-Response Relationship, Drug; Male; Osteoporosis; Parathyroid Hormone; Phosphorus; Rats; Rats, Inbred SHR; Serum Albumin; Time Factors | 2004 |
Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
Topics: Acid Phosphatase; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Injections, Intravenous; Isoenzymes; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptide Fragments; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase; Vitamins | 2004 |
The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Topics: Calcitriol; Calcium; Calcium Channel Agonists; Case-Control Studies; Epoxy Compounds; Female; Hemodialysis Solutions; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Time Factors | 2005 |
Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents; Bone Density; Calcitriol; Calcium; Comorbidity; Drug Therapy, Combination; Ethanol; Female; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus | 2006 |
[Influence of serum phosphate level for effects of OCT pulse therapy in hyper-PTH HD patients].
Topics: Calcitriol; Humans; Hyperparathyroidism, Secondary; Phosphorus; Pulse Therapy, Drug; Renal Dialysis; Retrospective Studies | 2005 |
[Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
Topics: Aged; Alkaline Phosphatase; Biomarkers; Calcitriol; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies; Time Factors | 2005 |
[Acute response of serum PTH and bone markers after injection of 1alpha,25 (OH)2D3 and 22-oxacalcitrol in hemodialysis patient].
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcitriol; Calcium; Female; Humans; Injections; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors | 2005 |
Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism.
Topics: Aged; Alkaline Phosphatase; Anticarcinogenic Agents; Biomarkers; Calcitriol; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Osteocalcin; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome; Ultrasonography | 2010 |
Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Topics: Aged; Biomarkers; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Parathyroid Hormone; Patient Care Planning; Phosphorus; Renal Dialysis; Vitamins | 2017 |